间质和/或腔内近距离放射治疗是阴道癌治疗的一个组成部分，近距离放射治疗 (BT) 已被证明可以改善局部控制、总体生存 (OS) 和无病生存 (DFS)。我们的研究目的是分析近距离放射治疗对阴道癌患者的疗效和安全性。2000年至2023年间，27名FIGO I-III期阴道癌患者接受了近距离放射治疗，联合或不联合外照射放疗（EBRT）和同时化疗。近距离放射治疗可以单独进行 PDR-近距离放射治疗，中位累积剂量高达 62.5 Gy (EQD2 = 63.9 Gy)，也可以联合 PDR-BT 加强治疗，中位剂量为 30.9 Gy (EQD2 = 30.4 Gy)。 HDR-BT 仅作为加强剂量施用，中位剂量为 25.5 Gy (EQD2 = 47.8 Gy)。原发淋巴结和盆腔淋巴结的 EBRT 中位剂量分别为 48.7 Gy 和 49.4 Gy。中位随访时间为 39 个月 (2-120)。 5/27 患者出现局部复发，整个患者群体的 5 年累积局部复发率为 18.5%。 5 年 OS 和 DFS 分别为 90% 和 68%。 I-II 期的 5 年 DFS 为 72%，III 期为 65% (p = 0.933)。 3/22 名患者 (13.6%) 记录了近距离放射治疗的 3 级晚期副作用，其中 1 名患者经历了 4 级毒性 (4.5%)。近距离放射治疗联合或不联合 EBRT 以及伴随化疗治疗阴道癌是一种安全有效的治疗选择，具有良好的疗效。局部控制和总体生存以及可接受的毒性。版权所有 © 2024。由 Elsevier Inc. 出版。

Interstitial and/or intracavitary brachytherapy is an integral part of the treatment of vaginal cancer Brachytherapy (BT) has shown to improve local control, overall survival (OS) and disease-free survival (DFS). The aim of our study was to analyze the efficacy and safety of brachytherapy in patients with vaginal cancer.Between 2000 and 2023, 27 patients with vaginal cancer in stage FIGO I-III were treated with brachytherapy with or without external beam radiotherapy (EBRT) and simultaneous chemotherapy. Brachytherapy has been performed either as PDR-brachytherapy alone with a median cumulative dose up to 62.5 Gy (EQD2 = 63.9 Gy) or with PDR-BT boost with median dose of 30.9 Gy (EQD2 = 30.4 Gy). HDR-BT was administered solely as boost with a median dose of 25.5 Gy (EQD2 = 47.8 Gy). The median dose of EBRT was 48.7 Gy and 49.4 Gy for primary and for pelvic lymph nodes.Median follow-up was 39 months (2-120). 5/27 patients developed local recurrences and the 5-year cumulative local recurrence rate for whole patient population was 18.5%. 5-year OS and DFS was 90% and 68%. 5-year DFS for Stage I-II was 72% and for Stage III 65% (p = 0.933). Grade 3 late side effects of brachytherapy were documented in 3/22 patients (13.6%), one patient experienced Grade 4 toxicity (4.5%).Brachytherapy with or without EBRT and concomitant chemotherapy for vaginal cancer is a safe and effective treatment option with excellent local control and overall survival and acceptable toxicity.Copyright © 2024. Published by Elsevier Inc.